Income Before Tax
Pre-Tax Income
Vertex Pharmaceuticals Pre-Tax Income decreased by 5.9% to $1.25B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 71.5%, from $730.40M to $1.25B. Over 4 years (FY 2021 to FY 2025), Pre-Tax Income shows an upward trend with a 14.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionIncome Before Tax
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
Higher values indicate stronger overall profitability and operational efficiency before tax impacts.
Detailed definition
Measures the profitability of the company after all operating and non-operating expenses have been deducted, but before...
Peer comparison
A standard GAAP metric used universally to compare pre-tax performance across different industries.
Metric ID:
income_before_taxHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$44.20M | $1.08B | $870.90M | $954.80M | $1.02B | $1.18B | $1.08B | $891.50M | $1.16B | $1.18B | $1.15B | $1.28B | -$3.39B | $1.22B | $1.14B | $730.40M | $1.28B | $1.30B | $1.33B | $1.25B |
| QoQ Change | — | >999% | -19.6% | +9.6% | +7.3% | +14.8% | -8.5% | -17.2% | +30.3% | +1.5% | -2.7% | +11.5% | -365.1% | +136.1% | -7.2% | -35.7% | +75.7% | +1.2% | +2.5% | -5.9% |
| YoY Change | — | — | — | — | >999% | +8.6% | +23.6% | -6.6% | +13.4% | +0.2% | +6.6% | +43.5% | -392.0% | +3.8% | -1.0% | -42.9% | +137.8% | +6.1% | +17.1% | +71.5% |
Range-$3.39B – $1.33B
CAGR+102.2%
Avg YoY Growth+144.2%
Median YoY Growth+7.6%
Pre-Tax Income at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's pre-tax income?
- Vertex Pharmaceuticals (VRTX) reported pre-tax income of $1.25B in Q1 2026.
- How has Vertex Pharmaceuticals's pre-tax income changed year-over-year?
- Vertex Pharmaceuticals's pre-tax income increased by 71.5% year-over-year, from $730.40M to $1.25B.
- What is the long-term trend for Vertex Pharmaceuticals's pre-tax income?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's pre-tax income has grown at a 14.2% compound annual growth rate (CAGR), from $2.73B to $4.64B.
- What does pre-tax income mean?
- Total profit earned before accounting for income tax obligations.